SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and rising volume have drawn attention, with traders linking the move to Starknets privacy and Bitcoin-DeFi initiatives and its post-quantum security narrative. Sentiment is broadly bullish on momentum and the projects technology, though some traders question whether gains can hold amid token-unlock and dilution concerns.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives proposed supply-squeeze update, which traders say could double INJs deflation rate if approved, is fueling bullish discussion alongside progress in tokenization and institutional finance. Optimists point to burns, staking and ecosystem growth, while skeptics remain wary of the tokens prolonged decline and question whether those developments will translate into sustained demand.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

Bitdeers AI/HPC expansion is drawing attention, particularly its announced long-term Norway data-center lease, while the companys at-the-market share offering has fueled concerns about dilution amid weak price action. Bulls point to the AI infrastructure opportunity alongside Bitcoin mining, while skeptics question whether the growth will translate into shareholder gains.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT traders are weighing a rebound against lingering concerns from the Wanchain bridge exploit and ongoing airdrop/unlock-related selling. Bulls point to the mainnet rollout, validator and partnership developments, and reported Coinbase availability as signs of adoption, while skeptics remain cautious about supply pressure and the exploits impact on confidence.

Wachovia Corporation, a financial holding company, provides commercial and retail banking services, and other financial services. Wachovia was a diversified financial services company based in Charlotte, North Carolina. Before its acquisition by Wells Fargo in 2008, Wachovia was the fourth-largest bank holding company in the United States based on total assets. Wachovia provided a broad range of banking, asset management, wealth management, and corporate and investment banking products and services. At its height, it was one of the largest providers of financial services in the United States, operating financial centers in 21 states and Washington, D.C., with locations from Connecticut to Florida and west to California.

Wells Fargo & Co.

Wells Fargo is drawing attention ahead of its Q3 earnings as bank shares face pressure from rising Treasury yields and concerns about margins and deposit costs. Traders are split between buying the pullbackciting Wells Fargos Morgan Stanley upgrade and improving prospects after the asset-cap removaland waiting for earnings to clarify the outlook.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention for a technical rebound, with traders watching a break above resistance near $26$27 and citing bullish chart patterns. Many are optimistic about its capped token supply and planned V4 and institutional-market expansion, while others remain frustrated by uneven price action; the breakout thesis is speculative.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

Bitcoins rebound and traders view that it may have bottomed are fueling bullish interest in MSTX, a 2x leveraged MSTR ETF. Some traders remain cautious about its volatility and leverage decay, with bearish options activity viewed by some as hedging rather than a directional bet.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is drawing attention amid a sharp pullback across uranium and nuclear stocks, with traders divided over whether the shares are forming a bottom or facing further pressure as enthusiasm for the nuclear theme cools. Cigar Lakes temporary production suspension added supply concerns, though Cameco said operations resumed and its production outlook was unchanged; bulls continue to cite long-term nuclear demand and Westinghouse exposure.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

ABTC is drawing attention as a volatile Bitcoin-mining and treasury play, with bullish traders linking potential rebounds to Bitcoin strength and short-squeeze speculation. Skeptics counter that the stocks steep post-reverse-split decline, dilution concerns and weak performance relative to Bitcoin undermine that thesis.

Alignment Healthcare, Inc. is a holding company, which offers a consumer-centric platform that delivers customized health care solutions to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. It offers health plan options through Alignment Health Plan, and partners with select health plans to help deliver better benefits at lower costs. The company was founded by John E. Kao in 2013 and is headquartered in Orange, CA.

Alignment Healthcare Inc

Alignment Healthcares largest California Medicare Advantage contract fell from four to 3.5 stars, putting its eligibility for quality bonus payments at risk and driving a sharp selloff. Traders debate how much this could weigh on future earnings, with some expecting the company to challenge the rating and others viewing the potential 2028 impact as substantial.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silence Therapeutics to Participate in Three September Investor Conferences

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast. Cantor Global Healthcare...

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs

Silence Therapeutics plc, (Nasdaq: SLN), (Silence or the Company), a global clinical-stage biotechnology company developing novel short interfering RNA (siRNA) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares...

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The Catalysts are Back: Socket Mobile Breaks Out While Biotechs Race Toward Major Milestones

Today's action is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones.

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.read more...

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with...

Silence Therapeutics Hits the Catalyst Zone—Divesiran Data Could Send SLN Into Overdrive

Silence Therapeutics (NASDAQ:SLN) is heading into a potentially decisive moment as investors await topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV). The company scheduled an August 10 conference call and webcast to discuss the results, putting its lead clinical program directly in the spotlight. With the Phase 2 study fully enrolled and topline data previously expected in the third quarter, the event represents a major potential inflection point for the clinical-stage biotech and its siRNA platform.

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for...

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call...

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow...

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc - ADR

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.11	--	--	N/A
Q2 '26	-$0.13	-$0.09	28.46%	BEAT
Q1 '26	-$0.13	-$0.11	14.93%	BEAT
Q4 '25	-$0.19	-$0.09	51.57%	BEAT
Q3 '25	-$0.19	-$0.15	19.81%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLN Earnings

Upcoming Earnings: Q3 '26

Historical Earnings